Johnson & Johnson (JNJ): Buying Isn’t for Growth Investors

If there’s one health-care stock every investor knows by name, it’s Johnson & Johnson (NYSE:JNJ). This industry titan makes everything from consumer health products to medical devices to pharmaceuticals, reaching into every niche of the medical sector. It’s a strong dividend stock with a history of stability — there’s seemingly some perk for every  J&J investor.

Johnson & Johnson (JNJ)However, growth investors might want to take a look elsewhere. For all J&J does right, it’s anything but a fast-growing, chart-topping stock for those looking for the best possible annual returns. While J&J isn’t short on financial growth and makes a great foundation for any portfolio, a few key trends should make growth investors think twice before doubling up on shares.

Core businesses, slow growth
J&J is much more than a medicine company, and is far more diverse than its Big Pharma rivals. It is heavily reliant on sales of consumer health products and medical devices. In 2012, these two segments made up more than 62% of all revenue.

Unfortunately for growth investors, these two segments aren’t exactly setting the markets on fire. Consumer health sales are a great, stable foundation for risk-averse investors, but there’s little growth to be had here: Revenue fell at five of the six consumer health businesses last year, with only oral-care sales remaining flat. With tightening consumer wallets and hospital budgets under pressure, expect that trend to keep up in the near future.

Medical devices can be a great growth driver: J&J proved as much when the company bought orthopedics firm Synthes last year in a $12 billion deal. That acquisition sparked a huge jump in the company’s orthopedics revenue. Unfortunately, J&J’s most recent earnings report has shown that without the Synthes deal, revenue growth has been elusive for the company’s medical device segments.

Orthopedics revenue should continue to grow in the future: Rival Stryker Corporation (NYSE:SYK) recently posted growing orthopedics revenue despite its troubles with hip implant recalls and pricing pressures in the industry, and age and obesity-related trends should keep demand high for years to come. J&J’s other medical device segments haven’t been so lucky recently, and slow, steady growth outside of orthopedics looks to stick around for some time as the medical device industry struggles.

If medical device revenue and consumer health sales aren’t growing at a good clip, pharmaceuticals can always drive growth. Unfortunately, while J&J’s drug business is top-notch, it’s not lighting up the markets like a fresh, new biotech firm.

Diluting the blockbuster drugs
J&J’s pharmaceutical business is massive, covering everything from oncology to immunology and more. That treatment diversity is a blessing for income investors and shareholders seeking stability in a volatile industry like health care, but for growth investors, it can be a curse.

The company reported strong growth in several promising drugs last year, including more than 300% year-over-year sales growth from likely future blockbuster prostate cancer treatment Zytiga. This wasn’t enough to ward off falling sales from patent expirations. Growth slipped from 8.8% in 2011 to just 4% last year, and while the future’s bright for J&J’s pharmaceutical business with potential future blockbusters such as diabetes-fighting Invokana, this segment’s diversity of drugs and therapies dilute the effect of up-and-coming drug candidates on overall growth.

This is a problem that affects Big Pharma companies across the sector, but major firms in pharmaceuticals and biotech have managed to grow significantly while concentrating on smaller, more focused drug portfolios. Consider Biogen Idec Inc. (NASDAQ:BIIB): The firm’s considerable focus on multiple sclerosis drugs exposes it to far more risk than Johnson & Johnson (NYSE:JNJ)’s well-diversified portfolio, but it’s still a far safer pick than up-and-coming biotech firms with murky futures. That hasn’t stopped Biogen Idec Inc. (NASDAQ:BIIB) shares from soaring more than 59% over the past year, nearly double J&J’s performance.

The problem with diversity
All of this adds up to the most important reason why J&J isn’t the best bet for growth investors: This company is simply too broad and diversified to realize chart-topping growth for any long period of time.

Other leading firms in the health-care field have caught on. Pfizer Inc. (NYSE:PFE) has made some of the strongest moves to concentrate on its core recently, selling its infant nutrition business to Nestle and spinning off its former animal health business, Zoetis Inc (NYSE:ZTS), in order to unlock shareholder value. These moves not only allowed Pfizer Inc. (NYSE:PFE) to concentrate on its high-growth, boom-or-bust pharmaceutical business, but also, as a secondary effect, made the stock attractive to growth investors by focusing the company’s future around a core designed for growth.

J&J’s diversification strategy isn’t bad business sense, and it’s a boon for investors craving stability in a volatile market. The stock’s even been one of the best performers on the Dow Jones index this year, as it’s outperformed the market. Yet even on the Dow alone, fellow blue-chip health-care rival Pfizer has topped J&J’s gains, to say nothing of the many other strong pharmaceutical and biotech companies surging this year. J&J’s a great, safe stock for any portfolio to build around, but if you’re looking for the best growth in the industry and are willing to take a chance, there are riskier — and potentially more rewarding — stocks around the sector than Johnson & Johnson (NYSE:JNJ).

The article Why Buying Johnson & Johnson Stock Isn’t for Growth Investors originally appeared on Fool.com.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!